Hyperuricemia
Conditions
Brief summary
Quercetin, a natural flavonoid found in various fruits and vegetables, has gained attention for its potential role in managing hyperuricemia. Emerging evidence suggests that quercetin may reduce plasma uric acid levels by inhibiting xanthine oxidase, an enzyme responsible for uric acid production. Additionally, its anti-inflammatory and antioxidant properties could help mitigate the oxidative stress and inflammation associated with hyperuricemia. As a result, quercetin supplementation offers a promising avenue for therapeutic intervention in conditions like gout and other uric acid-related disorders.
Detailed description
In the present retrospective cross-sectional observational study, the investigators assessed the potential pharmacological effect of supplemental quercetin on the plasma uric acid levels of health adults. These participants visited nutritional clinics in Italy during the Coronavirus disease (COVID-19) pandemic for general health check-up in real-life to enhance their immune system with supplements aimed at providing additional protection against COVID-19 infection. The supplements, either quercetin or probiotic Streptococcus salivarius K12 (BLIS K12), were advised randomly to the participants for 90 days, tailored to individual needs and in the absence of any pre-defined criteria.
Interventions
DIETARY_SUPPLEMENTQuevir® (Quercetin Phytosome®)
500 mg Quevir® (Quercetin Phytosome®) tablet
DIETARY_SUPPLEMENTBactoblis®
Probiotic Streptococcus Salivarius K12 (ATCC BAA-1024)
Sponsors
The University of Urbino Carlo Bo, Italy
Liaquat University of Medical & Health Sciences
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy adults * BMI between 18.5 and 29.9 kg/m² * Non-smoker * Consumtion of less than 3 units of alcohol per day
Exclusion criteria
* \- Plasma uric acid concentrations above 7 mg/dL * Diagnosis of endocrinological, metabolic, oncological, neurological, or bowel inflammatory disease diseases, gout, kidney stones
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in plasma uric acid level | 90 days | Supplement effect on plasma uric acid level |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in plasma triglycerides level | 90 days | Supplement effect on plasma triglycerides level |
| Change in plasma glucose level | 90 days | Supplement effect on plasma glucose level |
| Change in plasma insulin level | 90 days | Supplement effect on plasma insulin level |
| Change in plasma creatine phosphokinase level | 90 days | Supplement effect on plasma creatine phosphokinase level |
| Change in alanine transaminase level | 90 days | Supplement effect on liver function |
| Change in plasma cholesterol level | 90 days | Supplement effect on plasma cholesterol level |
| Change in alkaline phosphatase level | 90 days | Supplement effect on liver function |
| Change in gamma-glutamyl transferase level | 90 days | Supplement effect on liver function |
| Change in bilirubin level | 90 days | Supplement effect on liver function |
| Incidence of side effects | 90 days | Number of patients reporting side effects |
| Change in aspartate aminotransferase level | 90 days | Supplement effect on liver function |
Countries
Italy
Outcome results
None listed